ADC Therapeutics (ADCT) Projected to Post Quarterly Earnings on Thursday

ADC Therapeutics (NYSE:ADCT) is projected to post its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect ADC Therapeutics to post earnings of ($0.38) per share for the quarter. Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

ADC Therapeutics (NYSE:ADCT) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.14). The business had revenue of $18.84 million for the quarter, compared to the consensus estimate of $17.82 million. On average, analysts expect ADC Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

ADC Therapeutics Stock Up 4.0%

NYSE ADCT opened at $4.61 on Thursday. ADC Therapeutics has a 52 week low of $1.05 and a 52 week high of $4.74. The stock has a market capitalization of $518.06 million, a PE ratio of -2.93 and a beta of 1.99. The firm has a 50 day moving average of $3.73 and a two-hundred day moving average of $2.96.

Analyst Ratings Changes

Several research analysts have commented on ADCT shares. Wall Street Zen cut shares of ADC Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ADC Therapeutics in a report on Wednesday, October 8th. HC Wainwright lowered their price target on shares of ADC Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Thursday, October 16th. Finally, Guggenheim reiterated a “buy” rating and set a $10.00 price target on shares of ADC Therapeutics in a report on Wednesday, August 13th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.50.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ADCT. AQR Capital Management LLC boosted its holdings in shares of ADC Therapeutics by 411.1% in the 1st quarter. AQR Capital Management LLC now owns 201,170 shares of the company’s stock valued at $284,000 after buying an additional 161,808 shares in the last quarter. Creative Planning acquired a new position in shares of ADC Therapeutics in the 2nd quarter valued at $96,000. Nantahala Capital Management LLC acquired a new stake in ADC Therapeutics during the 2nd quarter worth $6,074,000. Bank of America Corp DE boosted its stake in ADC Therapeutics by 22.1% during the 2nd quarter. Bank of America Corp DE now owns 2,199,059 shares of the company’s stock worth $5,893,000 after purchasing an additional 397,905 shares during the period. Finally, Corient Private Wealth LLC acquired a new stake in ADC Therapeutics during the 2nd quarter worth $959,000. Institutional investors and hedge funds own 41.10% of the company’s stock.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.